COUR Pharma

Reprogramming the immune system to restore health in people suffering from autoimmune diseases

[COUR Pharma @CourPharma]

Later this week, members of our team will present on our antigen-specific immune tolerance approach to #Type1Diabetes at the #ADASciSessions. See the graphic below for details, and learn more about our #T1D program by visiting our website: https://t.co/DYwkYZCCRt

[COUR Pharma @CourPharma]

On #ClinicalTrialsDay, we thank the patients, families, and healthcare professionals advancing research in type 1 diabetes (T1D). Without you, trials like ours could not move forward. Visit our new site for info about our trial: https://t.co/Qk23B1xQSY

[COUR Pharma @CourPharma]

Attending @ImmunologyAAI’s #IMMUNOLOGY2026™? COUR’s Director of Immunology, Joseph Podojil, PhD, will present new data from our nanoparticle platform, including reversal of T1D in preclinical models. Learn more: https://t.co/euWa9FP8Bt #AAI2026

[COUR Pharma @CourPharma]

Our Director of Immunology, Joe Podojil, PhD, will speak at the 8th Treg-Directed Therapies Summit on advancing antigen-specific, non-cell therapy approaches for autoimmune diseases and clinical data in #PrimaryBiliaryCholangitis & #CeliacDisease. Details: https://t.co/o3dOfzxVmk

[COUR Pharma @CourPharma]

March is #AutoimmuneAwarenessMonth and recognizing the millions living with #AutoimmuneDiseases. At COUR, we’re advancing antigen-specific tolerance therapies designed to address the root cause of autoimmune disease-not just their symptoms.

More here: ttps://bit.ly/3PxAGnn

[COUR Pharma @CourPharma]

One-year data from the Phase 2a trial of our investigational therapy CNP-104 show sustained benefit in #PrimaryBiliaryCholangitis (#PBC):
· Improved ALP and bilirubin levels
· Durable effects across liver stiffness
· Favorable safety and tolerability
More: https://t.co/hW6J02QIWB

[COUR Pharma @CourPharma]

Our VP of Research, Adam Elhofy, PhD, will present at the 9th Annual Antigen-Specific Immune Tolerance Summit. He will highlight clinical signatures of tolerance observed in our program for #PrimaryBiliaryCholangitis. Learn more: https://t.co/UphHIGc76r

[COUR Pharma @CourPharma]

Our recent publication in @ScienceMagazine defines how COUR nanoparticles (CNPs) induce antigen-specific immune tolerance by activating the same pathway the immune system uses to maintain self-tolerance during apoptotic cell clearance. Read more: https://t.co/VlhVy09FxD

[COUR Pharma @CourPharma]

We are enrolling adults in a #ClinicalTrial of CNP-106, an investigational, disease-specific immune therapy for #MyastheniaGravis. The study explores a targeted immune approach that aims to improve MG symptoms.

Learn more: https://t.co/CeCeqz685x

[COUR Pharma @CourPharma]

We are a proud partner of the 9th Annual ASIT Summit. We look forward to connecting with our peers and discussing the latest innovations in immune tolerance in March 2026. Our VP of Research, Adam Elhofy, PhD, will present. Details: https://t.co/UphHIGc76r

[COUR Pharma @CourPharma]

We recently hosted the @ChiBiomed Entrepreneurial Fellows at our office. We discussed careers in biopharma and dug into the science behind our approach to antigen-specific immune tolerance. We are grateful for our collaboration and inspired by these future industry leaders.

[COUR Pharma @CourPharma]

Join us in Phoenix, AZ at @MyastheniaOrg’s Community Health Fair on Saturday, December 6. Meet our team and learn about the ongoing #ClinicalTrial of our investigational antigen-specific treatment, CNP-106 for #MyastheniaGravis. Register here: https://t.co/87DsHfcpzW

[COUR Pharma @CourPharma]

We’re testing investigational therapy CNP-103 in a Phase 1/2 trial in patients with #Type1Diabetes as a novel approach to maintain insulin production by slowing the immune attack on beta cells. Learn more: https://t.co/NOT4osFLrl

[COUR Pharma @CourPharma]

Today is #WorldDiabetesDay. At COUR, we hope our work to develop an immune tolerance approach will one day make life easier for people managing #Type1Diabetes #T1D at work, at home & everywhere in between. Learn more about #WDD2025 #DiabetesLife campaign https://t.co/zOS3hvWMcT

[COUR Pharma @CourPharma]

We’re proud that COUR has been named one of @BioSpace’s 2026 Best Places to Work! Our team of curious, driven individuals bring creativity & collaboration to everything we do as we redefine what’s possible in the fight against autoimmune disease: https://t.co/7ASutxCmkH

[COUR Pharma @CourPharma]

Don’t miss our two posters at @AASLDTweets’ #TLM25. The posters highlight data for our investigational tolerogenic therapy, CNP-104, which is being evaluated for the treatment of primary biliary cholangitis (PBC). Learn more about CNP-104 here: https://t.co/DYwkYZCCRt

[COUR Pharma @CourPharma]

Team COUR was proud to join @BreakthroughT1D’s Chicago Walk last month in support of the #Type1Diabetes community. Together, we’re walking toward a future where innovative science and collective action will change lives for people with T1D.

[COUR Pharma @CourPharma]

Our CMO, Paul Peloso, MD, is featured in @t1d_strong_org’s latest blog post. Read more about our work to advance an antigen-specific immune tolerance therapy that could represent a true disease-modifying treatment for those newly diagnosed with T1D: https://t.co/Uq4faDynO5

[COUR Pharma @CourPharma]

Congratulations to Darshil Patel, PhD, Director of R&D, who was named to @BioSpace’s inaugural 40 Under 40 list. Read how Darshil is leading teams as we advance our antigen-specific immune tolerance programs into the clinic for several autoimmune disease: https://t.co/W9lojkmntS

[COUR Pharma @CourPharma]

Last week we welcomed the @IAmBiotech team to our new office and lab spaces as part of #BIOontheAmericanRoad. We connected with @IllinoisBiotech and shared how we are advancing the next generation of disease-modifying therapies for #AutoimmuneDiseases.

[Biotechnology Innovation Organization @IAmBiotech]

#BIOontheAmericanRoad has officially arrived in Chicago, and the first stop included a tour of @CourPharma’s new office and lab spaces. COUR leadership discussed how the biotech leader is developing the next generation of disease-modifying therapies for people living with autoimmune disease. BIO President and CEO John F. Crowley also met with John Conrad, CEO of @IllinoisBiotech, an Illinois BIO affiliate and a representative of the Illinois Department of Commerce and Economic Opportunity.